Analysis
Centinel Spine Holdco, Inc. publicly filed a Form S-1 with the SEC on Oct. 7, 2026, after earlier submitting confidential draft registration statements, a DRS and a DRS/A, according to SEC filings. Centinel Spine is a spinal-device maker focused on total disc replacement, built around its prodisc product line.
The offering is structured as an umbrella partnership C-corporation: public investors would buy Class A common stock in Holdco, whose primary asset is newly issued Series A common units in the operating company, Centinel LLC. Pre-IPO owners would hold Class B shares carrying voting power but no direct economic interest in Holdco, per the DRS/A. The S-1 still lists blank placeholders for the share count, price range and expected proceeds, marking it as a preliminary prospectus still subject to SEC review rather than a priced, imminent offering. The company describes itself in the filing as an emerging growth company and smaller reporting company.
“Pre-IPO owners would hold Class B shares carrying voting power but no direct economic interest in Holdco, per the DRS/A.”
According to proceeds language in the DRS, Centinel LLC intends to use IPO proceeds to pay offering and reorganization costs, repay its 2023 Credit Agreement and loan facilities, and fund sales, R&D, capital expenditures and working capital. The company took a $60 million senior secured growth loan from SLR Capital Partners in early 2025 to finance cervical spinal disease treatments, with Latham & Watkins advising on that facility.
